Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Phase III Study of KC-8025 in Primary Biliary Cholangitis Patients with Inadequate Response or Intolerance to Ursodeoxycholic Acid
jRCT2021250033Phase 3Recruiting
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of seladelpar in primary biliary cholangitis (PBC), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoints: Adverse events and Other safety endpoints. Started Mar 2026; status: recruiting.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on jRCT2021250033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250033.